Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ: CCCC )

8.030 +0.490 (+6.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 532,310
Open 7.510
Bid (Size) 7.830 (1)
Ask (Size) 8.200 (5)
Prev. Close 7.540
Today's Range 7.350 - 8.080
52wk Range 4.840 - 51.21
Shares Outstanding 48,797,226
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
C4 Therapeutics's Return On Capital Employed Overview
C4 Therapeutics (NASDAQ:CCCC) brought in sales totaling $7.65 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 101.94%, resulting in a loss of $31.62 million. 
Via Benzinga
C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers
C4 Therapeutics, Inc. (C4T) (NASDAQ: CCCC) has dosed the first patient in the Phase 1/2 clinical trial of its drug candidate CFT8634, for the treatment of SMARCB1-perturbed cancers, including synovial... 
Via Benzinga

Performance

YTD
-75.84%
-75.84%
1 Month
+22.97%
+22.97%
3 Month
-67.96%
-67.96%
6 Month
-75.06%
-75.06%
1 Year
-79.31%
-79.31%

More News

Read More
C4 Therapeutics: Q1 Earnings Insights
Via Benzinga
31 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Where C4 Therapeutics Stands With Analysts
Via Benzinga
66 Biggest Movers From Yesterday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Via Benzinga
BMO Capital Maintains Outperform Rating for C4 Therapeutics, Lowers Price Target To $20
Via Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Via Benzinga
Why C4 Therapeutics Stock Is Plunging Today
Via Benzinga
C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
28 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022
Via Benzinga
51 Biggest Movers From Yesterday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
Via Benzinga
87 Biggest Movers From Yesterday
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.